SVB Wealth’s Cogent Biosciences COGT Stock Holding History

SVB Wealth’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-539	Closed	-$3.23K	–	756
2025 Q1	$3.23K	Buy	+539	New	+$4.23K	﹤0.01%	1123

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SVB Wealth's COGT Position: Q2 2025 in Review

SVB Wealth sold out of Cogent Biosciences (COGT) in Q2 2025, closing a stake of 539 shares — an estimated $3.23K sold.

SVB Wealth first reported a position in COGT in Q1 2025 and held it in 1 quarter. The position peaked at $3.23K in Q1 2025. 180 funds tracked by Wall St. Rank hold COGT as of Q2 2025.

SVB Wealth reported no remaining Cogent Biosciences position as of Q2 2025 after selling out during the quarter.
SVB Wealth sold 539 Cogent Biosciences shares in Q2 2025, an estimated $3.23K.
SVB Wealth first reported a position in Cogent Biosciences in Q1 2025 and held it in 1 quarter.
SVB Wealth's Cogent Biosciences position peaked at $3.23K in Q1 2025.
180 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2025.

Based on SVB Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.